[Photo News] ASCO returns to full strength, with Korean firms actively engaged
2023-06-05 Kim Yun-mi
CHICAGO, Ill. -- By Kim Yun-mi/Korea Biomedical Review correspondent -- The annual meeting of the American Society of Clinical Oncology (ASCO 2023), the world's largest cancer conference, has successfully returned to full strength following a temporary pause during the Covid-19 pandemic.
Packed with oncology experts and health professionals from around the world, ASCO 2023 is taking place at McCormick Place in Chicago, U.S. this week until Tuesday.
Opening sessions and major oral presentations at the event drew a crowd of thousands, with lecture halls packed with cancer professionals. The poster sessions also garnered significant attendance and engagement.
ASCO 2023 revolves around the theme "Partnering With Patients," and the exhibit hall showcases several ASCO-sponsored patient support booths. These booths, categorized by cancer type, facilitate meaningful connections between clinicians and patients.
Furthermore, a wide range of companies, encompassing pharmaceuticals, biotechnology, and AI-related sectors, have arranged booths to showcase cutting-edge technologies and cancer research, capturing the interest of attendees.
Notably, major Korean pharmaceutical and biotech firms have also established booths to promote their global expansion efforts.
The American Society of Clinical Oncology Annual Meeting (ASCO 2023) is being held at McCormick Place in Chicago from June 2 to 6. The meeting is bustling as ever, with thousands of clinicians and industry representatives in attendance.
Experts flocked to the opening sessions and oral presentations to see the latest cancer research being presented for the first time at ASCO 2023.
Pictured here is a patient support booth organized by ASCO. The booths were designed by the organizers to align with the event theme of "Partnering With Patients.” The booths were organized by cancer type to support communication between clinicians and patients.
At the Korea Pavilion booth, operated by the National Clinical Trials Support Foundation (KoNECT), a total of 15 organizations including Korean pharmaceutical and biotech companies, clinical trial contract research organizations, consulting firms, and data solution companies participated in the event to explore global partnership opportunities. The photo shows LSK Global PS, the largest CRO in Korea, and JNPMEDI, a company specializing in digital platforms, at the Korea Pavilion booth.
On the left is the booth of AVEO, a pharmaceutical company acquired by LG Chem last year. In the center is Hanmi Pharmaceutical's booth featuring Rolontis (Rolvedon in the U.S.), Hyaluma (SynoJoynt in the U.S.), and Oraxol. On the right is a booth prepared for global promotion by Lunit, which is presenting a total of 16 abstracts at ASCO 2023.
Many companies from various industries such as AI-based diagnostic and genomic analysis, digital platforms, CROs, and patient research are participating in ASCO 2023.
AstraZeneca and Novartis had the largest booths at the event.
Attendees take a break at the popular Lake Michigan Lounge at McCormick Place.